Ironwood Pharmaceuticals, Inc.
IRWDNASDAQHealthcare● Active
$3.29
$-0.02(-0.60%)
Market Cap$541576770
P/E Ratio—
52W High$5.78
52W Low$0.56
Ironwood Pharmaceuticals, Inc. (IRWD) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
IRWD · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 7, 2026EPS Actual
$0.24
Est. $0.07 · +242.9%
Revenue
$0.11B
Est. $0.09B · +15.6%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 7, 2026
After Market Close
▲ Beat EPS▲ Beat Revenue✓ 1-Quarter EPS Beat Streak
IRWD reports quarterly as a NASDAQ-listed Drug Manufacturers - Specialty & Generic company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 6, 2026 | $0.26 | — | — | — | $0.12B | — |
| ▲ Q2 FY2026 | May 7, 2026 | $0.07 | $0.24 | +242.9% | $0.11B | $0.09B | +15.6% |
| ▼ Q1 FY2026 | Feb 25, 2026 | $0.02 | -$0.01 | -150.0% | $0.05B | $0.05B | -6.3% |
| ▲ Q4 FY2025 | Nov 10, 2025 | $0.09 | $0.24 | +166.7% | $0.12B | $0.05B | +139.7% |
| ▲ Q3 FY2025 | Aug 7, 2025 | -$0.02 | $0.14 | +800.0% | $0.09B | $0.08B | +9.5% |
| ▼ Q2 FY2025 | May 7, 2025 | -$0.05 | -$0.14 | -180.0% | $0.04B | $0.07B | -42.1% |
| ▼ Q1 FY2025 | Feb 27, 2025 | $0.10 | $0.02 | -80.0% | $0.09B | $0.07B | +35.1% |
| ▼ Q4 FY2024 | Nov 7, 2024 | $0.08 | $0.02 | -75.0% | $0.09B | $0.09B | -1.0% |
Q3 FY2026
Aug 6, 2026
EPS Actual
—
EPS Est.
$0.26
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 7, 2026Beat
EPS Actual
$0.24
EPS Est.
$0.07
EPS Surpr.
+242.9%
Revenue
$0.11B
Q1 FY2026
Feb 25, 2026Miss
EPS Actual
-$0.01
EPS Est.
$0.02
EPS Surpr.
-150.0%
Revenue
$0.05B
Q4 FY2025
Nov 10, 2025Beat
EPS Actual
$0.24
EPS Est.
$0.09
EPS Surpr.
+166.7%
Revenue
$0.12B
Q3 FY2025
Aug 7, 2025Beat
EPS Actual
$0.14
EPS Est.
-$0.02
EPS Surpr.
+800.0%
Revenue
$0.09B
Q2 FY2025
May 7, 2025Miss
EPS Actual
-$0.14
EPS Est.
-$0.05
EPS Surpr.
-180.0%
Revenue
$0.04B
Q1 FY2025
Feb 27, 2025Miss
EPS Actual
$0.02
EPS Est.
$0.10
EPS Surpr.
-80.0%
Revenue
$0.09B
Q4 FY2024
Nov 7, 2024Miss
EPS Actual
$0.02
EPS Est.
$0.08
EPS Surpr.
-75.0%
Revenue
$0.09B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $0.37 | $0.39 | $0.41 | 1 |
| Q3 FY2028 | $0.35 | $0.37 | $0.39 | 1 |
| Q2 FY2028 | $0.33 | $0.35 | $0.37 | 1 |
| Q1 FY2028 | $0.29 | $0.30 | $0.32 | 1 |
| Q4 FY2027 | $0.33 | $0.35 | $0.37 | 1 |
| Q3 FY2027 | $0.31 | $0.33 | $0.35 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $0.1B | $0.1B | $0.1B | 1 |
| Q3 FY2028 | $0.1B | $0.1B | $0.1B | 1 |
| Q2 FY2028 | $0.1B | $0.1B | $0.1B | 1 |
| Q1 FY2028 | $0.1B | $0.1B | $0.1B | 1 |
| Q4 FY2027 | $0.1B | $0.1B | $0.1B | 1 |
| Q3 FY2027 | $0.1B | $0.1B | $0.1B | 1 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 7, 2026 | +242.9% | $4.83 | $4.17 | -13.66% |
| ▼ Q1 FY2026 | Feb 25, 2026 | -150.0% | $3.79 | $3.36 | -11.35% |
| ▲ Q4 FY2025 | Nov 10, 2025 | +166.7% | $1.92 | $2.53 | +31.77% |
| ▲ Q3 FY2025 | Aug 7, 2025 | +800.0% | $0.81 | $0.88 | +9.32% |
| ▼ Q2 FY2025 | May 7, 2025 | -180.0% | $0.93 | $0.79 | -14.55% |
| ▼ Q1 FY2025 | Feb 27, 2025 | -80.0% | $1.71 | $1.62 | -5.26% |
| ▼ Q4 FY2024 | Nov 7, 2024 | -75.0% | $5.04 | $4.66 | -7.54% |
| ▼ Q3 FY2024 | Aug 8, 2024 | -103.6% | $6.01 | $4.05 | -32.61% |
Q2 FY2026-13.66%
Report Date
May 7, 2026
EPS Beat/Miss
+242.9%
Price Before
$4.83
Price After
$4.17
Q1 FY2026-11.35%
Report Date
Feb 25, 2026
EPS Beat/Miss
-150.0%
Price Before
$3.79
Price After
$3.36
Q4 FY2025+31.77%
Report Date
Nov 10, 2025
EPS Beat/Miss
+166.7%
Price Before
$1.92
Price After
$2.53
Q3 FY2025+9.32%
Report Date
Aug 7, 2025
EPS Beat/Miss
+800.0%
Price Before
$0.81
Price After
$0.88
Q2 FY2025-14.55%
Report Date
May 7, 2025
EPS Beat/Miss
-180.0%
Price Before
$0.93
Price After
$0.79
Q1 FY2025-5.26%
Report Date
Feb 27, 2025
EPS Beat/Miss
-80.0%
Price Before
$1.71
Price After
$1.62
Q4 FY2024-7.54%
Report Date
Nov 7, 2024
EPS Beat/Miss
-75.0%
Price Before
$5.04
Price After
$4.66
Q3 FY2024-32.61%
Report Date
Aug 8, 2024
EPS Beat/Miss
-103.6%
Price Before
$6.01
Price After
$4.05
Avg Beat Reaction+9.14%
Avg Miss Reaction-14.26%
Beat Rate3 / 8 quarters
Largest Move-32.61% (Q3 FY2024)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: IRWD ends December
Ironwood Pharmaceuticals, Inc. (IRWD) most recently reported earnings on May 7, 2026 for Q2 FY2026, posting EPS of $0.24 — beating the analyst consensus of $0.07 by +242.9%. The next IRWD earnings date is expected around September 1, 2026.
Each quarter, investors track IRWD earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. IRWD revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
IRWD's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
IRWD earnings · 5 questionsIronwood Pharmaceuticals, Inc.'s next earnings report is expected around September 1, 2026. IRWD typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; IRWD historically reports after market close (AMC).
IRWD earnings datewhen is IRWD earningsIRWD next earnings datewhen does IRWD report earningsIRWD earnings calendar
▸ Source: FMP · Ironwood Pharmaceuticals, Inc. SEC filings · US GAAP · Ironwood Pharmaceuticals, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026